Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics

CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale

17-Aug-2009 - USA

Joseph F. Finn, Jr.,C.P.A. announced that the PRX-07034 Therapeutics - CNS Phase 2 will be part of the intellectual property offered for sale at theSeptember 30, 2009 auction.

The PRX-07034 Therapeutics - CNS Phase 2 is a small molecule, oral 5HT6 antagonist for cognitive impairment associated with schizophrenia (CIAS). The Company has completed Phase 1 in obesity with racemic compound and completed Phase 1 with chiral compound. It has an open IND and a significant quantity of chiral API available.

The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction on September 30, 2009.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...